Elbert Glover


Elbert D. Glover, PhD is a researcher and writer in the field of tobacco addiction and smoking cessation. He is Professor of Public Health and Chair of the Department of Behavioral and Community Health at the University of Maryland at College Park School of Public Health.

Biography

He was born at the Kingsville Naval Base in Kingsville, Texas in 1945 where his father was stationed in the Navy. He is the oldest of 8 children born to a white father and a Mexican mother. Upon graduation from Roy Miller High School in Corpus Christi, Texas in 1963, he attended Texas Tech University on a football scholarship and graduated from Texas Tech University in 1969. In 1972, he received a masters degree from Texas A&I University and in 1977 a PhD from Texas Woman's University, all in Health Education. He has served as a professor at Texas A&M University, University of Kansas, Texas Christian University, Texas Woman's University, Texas College of Osteopathic Medicine, Oklahoma State University, East Carolina University, Penn State University, West Virginia University School of Medicine, and the University of Maryland at College Park School of Public Health. At the University of Maryland he served as chair of the Department of Behavioral and Community Health, and founding director of the Center for Health Behavior Research. Glover has 3 children, two males (Jason and Jeremiah) with a previous marriage and a daughter (Paris) with his current marriage.

Research

His primary research interest is the development of cessation aids for people interested in stopping the use of tobacco. He has conducted pivotal clinical trials with the use of all delivery forms of nicotine available on the US and European markets, including gum, transdermal patches, oral nicotine inhalers, nasal spray, and sublingual tablets. He also conducted pivotal trials with bupropion (Zyban, a monocyclic antidepressant) and varenicline (Chantix, a nicotine receptor and partial agonist) which resulted in both being approved for use in the US. In addition, he has studied the use of lobeline as a nicotine blocker,[1] and various psychoactive substances including anti-depressants and anti-anxiety agents. He has also investigated rimonabant (an endocabinnoid), varenicline (a nicotine receptor partial agonist)[2] and 3′AmNic-rEPA (a nicotine conjugate vaccine).[3]

He has received major research grants from the government U.S. Department of Education, Centers for Disease Control, National Cancer Institute, National Institute of Drug Abuse, and National Institutes of Health. He has also received major grants from the manufacturers of the smoking cessations aids or pharmaceuticals ALZ Corporation, AstraZeneca, Bristol-Myers Squibb, Burroughs Wellcome, Ciba-Geigy, DrugAbuse Sciences, DynaGen, Eli Lilly, Glaxo Wellcome, Healthcare Products Development, KABI Pharmacials, Knoll Pharmaceuticals, LEO Pharmaceuticals, Marion Merrell Dow, NABI Pharmaceuticals, Pharmacia, Pfizer, Sano, Sanofi-Synthelabo, SmithKline Beecham, Parke-Davis, Takeda, and Upjohn.[4]

Professional accomplishments

His research has resulted in his authoring or co-authoring more than 200 professional publications and receiving approximnately $45 millon dollars in grant funding primarily in the area of tobacco. He has delivered over 550 invited medical grand rounds/workshops on the subject to physicians and also presented 335 national and international professional presentations to various medical and health professional organizations.

Glover is publisher and editor of the American Journal of Health Behavior, Health Behavior and Policy Review and Tobacco Regulatory Science. He is the founder and first president of the American Academy of Health Behavior (AAHB),[5] and in 2003 received their Distinguished Scholar Award. In 2005 he received the Alliance Scholar for AAHPERD and in 2008 received the coveted American Academy of Health Behavior Research Laureate Medallion for his contribution to health behavior research. As the founder of the American Academy of Health Behavior was awarded the Lifetime Achievement Award by the Academy. He is a fellow of the American Academy of Health Behavior, the American School Health Association & the Royal Institute of Public Health.

Public work

Glover has appeared on many television programs, including Dateline, 20/20, The Charlie Rose Show, Good Morning America, PM Magazine, Health Talk America, MD-TV, CBS Morning News, Peter Jennings News World Report, and NBC Evening News. His research has been featured in numerous popular publications such as Ladies Home Journal, Newsweek, Readers Digest, Seventeen, Time, and USA Today.

He serves in various capacities primarily as reviewer for 20 key health academic journals and/or publications among these are the American Journal of Public Health, Addictive Behaviors, NCI Journal, Journal Clinical Advances in Smoking Cessation, Physician and Sportsmedicine, Medical Self-Care, Public Health Reports, American Journal of Health Education, Journal of School Health, Journal of Family Practice, Journal of Alcohol and Drug Education, Advances in Dental Research, Mayo Clinic Proceedings, Southern Medical Journal, Nicotine and Tobacco Research, Drug Discovery Today, and the Journal of the American Medical Association.

References

  1. ↑ "A Multicenter Phase 3 Trial of Lobeline Sulfate for Smoking Cessation" American Journal of Health Behavior, 34(1), January 2010 , 101-109
  2. ↑ "Varenicline: progress in smoking cessation treatment", Expert Opinion on Pharmacotherapy August 2007, 8(11) 1757-1767 doi:10.1517/14656566.8.11.1757
  3. ↑ "Immunogenicity and Smoking-Cessation Outcomes for a Novel Nicotine Immunotherapeutic" Clinical Pharmacology & Therapeutics 89, 392-399 (March 2011) doi:10.1038/clpt.2010.317
  4. ↑
  5. ↑ "Formation and Early History of The American Academy of Health Behavior" American Journal of Health Behavior, 34(5), September 2010 , 563-572.

External links

This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.